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Effects of pan-HDAC inhibition on cardiac Na + current density 207
To examine the effect of pan-HDAC inhibition on functional cardiac I Na , cultured NMVMs were 208 incubated overnight with 50 or 100 nM TSA, 1 or 5 μM VOR, or 10 nM FK228 and whole cell 209 patch clamp experiments were performed the next day (18-24 hrs later). To activate I Na , NMVM 210 membrane potential (V m ) was depolarized between -90 and +60 mV in 150 ms, 5 mV increments 211 from a V h of -120 mV. Examples of I Na current traces elicited from control, 100 nM TSA, 1 μM 212 VOR, and 10 nM FK228 treated NMVMs are illustrated in Figures 1A-D. Peak I Na density 213 decreased from control values of -36.2 ± 2.8 pA/pF to -13.7 ± 2.5 pA/pF with 100 nM TSA, 214 -17.6 ± 1.7 pA/pF with 5 μM VOR, and -15.1 ± 2.0 pA/pF with 10 nM FK228 (Figs. 1F-H). 215
Cellular input capacitance values were not significantly changed from control values (22.5 ± 1.4 216 pF, n=20) except at the highest concentrations of TSA (100 nM; 15.3 ± 0.7 pF, n=17) and VOR 217 (5 μM; 16.2 ± 0.7 pF, n=24) tested. The results are consistent with a pan-HDAC inhibitor-218 induced reduction in peak cardiac I Na irrespective of whether the HDAC inhibitor belongs to the 219 hydroxamate or cyclic peptide chemical group of HDAC inhibitors. 220 221 Persistent activation of I Na , caused by mutations in the Na V 1.5 sodium channel protein that 222 inhibit inactivation (e.g. ΔKPQ) or the α-sodium channel toxins like aconitine, are known to 223 cause cardiac arrhythmias via induction of early afterdepolarizations (EADs) (8, 65). Thus, we 224 measured the steady state current values at 100 ms for all control, 100 nM TSA, 1 μM VOR, and 225 10 nM FK228 experiments. Linear regression analyses of the whole cell current measured at the 226 +0.44 pA/mV for Control, TSA, VOR, and FK228, respectively) of all four datasets. The y-229 intercepts were significantly (p<0.05) more negative (19 pA inward) for TSA and significantly 230 more positive (6 pA outward) for FK228 relative to Control and VOR values. Taken together, 231 there is no evidence of an increase in the late I Na current in ventricular cardiomyocytes with 232 either of the clinically approved HDAC inhibitors tested. 233
234
I Na activation and inactivation 235
A slight positive shift in the activation voltage is apparent in the I Na current-voltage relationships 236 in Figs. 1F-H, so the peak sodium conductances (gNa) were calculated by dividing the 237 normalized peak I Na density values by (V m -E Na ) for each I-V curve in Fig. 1 and normalized by 238 dividing by the average maximum gNa ( g Na) for each experimental group. The calculated 239
Nernst potential for Na + (E Na ) was +35 mV and the experimental reversal potential (E rev ) values 240 were within 5 mV or ±1 pA/pF of E Na for all experimental groups. The V m -dependent activation 241 curves for TSA, VOR, and FK228 ( Fig. 2A-C) illustrate a +3 to +8 mV shift in the half 242 activation voltage (V ½act ) for all three pan-HDAC inhibitor experimental groups. Since I Na 243 activation was slightly affected by the HDAC inhibitor treatments, I Na inactivation was examined 244 using a prepulse protocol illustrated in Fig. 2E . The highest inhibitory concentrations of TSA 245 (100 nM) and VOR (5 μM) tested shifted the control I Na half-inactivation voltage (V ½inact ) of -83 246 mV by less than ±1 mV (Fig. 2D) . The effect of FK228 on I Na inactivation was not examined. 247
The small positive shift in the I Na activation curves without an accompanying change in the 248 inactivation curve decreases the V m -dependent "window" for persistent I Na activation (Fig. 2F) . 249
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The time-dependence of I Na inactivation was also examined by curve-fitting the decaying phase 251 of the I Na traces with a first-order exponential function. The V m -dependent inactivation time 252 constants (τ h ) were significantly slower in the -60 to -45 mV range for 100 nM TSA and 1 μM 253 VOR, but not for 10 nM FK228 (Fig. 3A-C) . There was no difference in the inactivation rates 254 between control and HDAC inhibitor treated ventricular cardiomyocytes within the -40 to -10 255 mV range, suggesting that the slow τ h values at low activating voltages seen with pan-HDAC 256 inhibition result from the positive shift in the activation curves ( Fig. 2A-C) and that I Na 257 inactivation rates were otherwise unaffected. 258 259
hiPSC cardiomyocytes 260
To assess whether the pan-HDAC inhibitor-induced decrease in cardiac I Na occurs in human 261 ventricular myocytes, human induced pluripotent stem cell derived cardiomyocytes (hiPSC-262 CMs) were treated with 1 μM VOR and I Na whole cell patch clamp experiments were performed 263 (Fig. 4) . In hiPSC-CMs, the recommended human therapeutic dose of VOR reduced cardiac I Na 264 density by 52% relative to control experiments, indicating that NMVMs are a valid experimental 265 model for studying the effects of HDAC inhibitors on cardiac I Na . The mean whole cell current, 266 measured between 100 and 150 ms, did not reveal any increase in late inward currents in the 267 VOR hiPSC-CM group relative to the control group, consistent with our findings in NMVMs 268 suggesting that late I Na was not induced by clinically relevant HDAC inhibitor treatments. 269 270 Na V 1.5 expression 271
Experiments in NMVMs and hiPSC-CMs consistently indicate that pan-HDAC inhibition 272 reduced I Na density, but the molecular basis for the decrease in cardiac I Na is unknown. The shift 273 did reduce Scn5a mRNA levels by 50% (N = 2), but did not reach statistical significance (p> 282 0.05). However, Western blot analyses, performed in triplicate, revealed that Na V 1.5 protein 283 levels were significantly reduced at all concentrations of TSA and VOR tested. The decrease in 284 I Na density correlates closely (within 15-25% deviation from unity) with the reduction in Na V 1.5 285 protein levels for both TSA and VOR, suggesting that the molecular basis for the pan-HDAC 286 inhibitor induced decrease in cardiac I Na is the dose-dependent reduction in Na V 1.5 protein 287 expression. Real-time PCR results with10 nM FK228 exhibited qualitatively similar abundances 288 for the Chd2, Gja1, Scn5a, and Slc8a genes and a significant reduction in their mRNA levels 289 relative to control values for all except the Scn5a gene transcript levels (Fig. 5E) . 290 291
Inhibition of cardiac HDAC activity by romidepsin 292
To correlate the decreases of cardiac I Na and Cx43 mRNA expression levels with the HDAC 293 inhibitory activity of FK228, the total NMVM HDAC activity was measured using a fluorimetric 294 not Na V 1.5 is a substrate for N e -lysine acetylation is currently unknown, so we subjected mouse 361 and human Na V 1.5 sequences to N e -lysine acetylation site analysis using the PHOSIDA website 362 (18). This bioinformatic analysis predicted two high probability (>90%) cytoplasmic acetylation 363 sites near the domain II and IV S4 segments known to be involved in V m -dependent activation 364 (Fig. 7A) . To determine if Na V 1.5 is acetylated, we injected six adult C57BL/6 mice with 10mg/kg TSA or DMSO/saline control i.p. injections for 5 days and immunoprecipitated the 366 ventricular heart lysates with anti-Na V 1.5 antibodies. Subsequent immunoblotting for acetylated 367 protein with an anti-acetyl-lysine (Ac-K) antibody revealed an increase in acetylated Na V 1.5 368 protein with TSA treatments (Fig. 7B,C) . The human and murine Na V 1.5 proteins possess 94% 369 sequence identity, hence we hypothesize that acetylation of K830 and K1644 (K1641 in the 370 human sequence) may account for the small depolarizing shift in the I Na activation curve and the 371 slowing of the inactivation rate at low activation potentials seen with pan-HDAC inhibition 372 (Figs. 2 and 3 ). This postulated acetylation-dependent shift of Na V 1.5 activation decreased the 373 V m -dependent window for prolonged activation of I Na (window current) and is unlikely to 374 account for the observed decrease results in I Na density, which correlates closely with the 375 decreased levels of Na V 1.5 protein. Identification of the actual Na V 1.5 acetylation sites will 376 require future liquid chromatography-electron spray ionization tandem mass spectroscopic 377 analyses of IP-enriched and/or SDS-PAGE proteolytic Na V 1.5 peptide digests (32). 378
379
There are nearly 500 Na V 1.5 mutations associated with cardiac arrhythmias including long QT 380 (LQT3) syndrome, Brugada syndrome (BrS), cardiac conduction disease (CCD), sick sinus 381 syndrome (SSS), and atrial fibrillation (AF) (13, 40, 51, 52, 65, 75). Na V β1-4 subunits also 382 contribute to LQT and AF cardiac arrhythmias (43, 66, 67). Approximately 75% of these 383 mutations cause loss of Na V 1.5 function except those involved in LQT and some AF 384 arrhythmias. Gain-of-function Na V 1.5 mutations typically increase activation or decrease 385 inactivation, resulting in a net increase of a persistent (sustained) or late I Na that prolongs action 386 potential duration and enhances the occurrence of early afterdepolarizations (EADs) (43, 65). For 387 example, expression of the Na V 1.5F1486del LQT mutation increased late I Na and produced
Scnb1
-/-mice and ischemic heart failure dog hearts produced increases in late I Na and 390 arrhythmias, thus indicating a role for neuronal isoforms in cardiac arrhythmogenesis (33, 44).
slow conduction velocity leading to arrhythmias including BrS, SSS, and CCD (6, 56, 61, 67). 394
Peak I Na density and gap junction conductance (g j ) are primary determinants of myocardial 395 conduction velocity and reductions in both of these factors will slow conduction and increase the 396 vulnerability to reentrant arrhythmias (30, 62). BrS arrhythmias frequently develop in the right 397 ventricle which is more susceptible to conduction slowing secondary to Na V 1.5 dysfunction (49, 398 51). 
